Clinical predictors of thiopurine-related adverse events in Crohn's disease

Table 2 Adverse events n (%)

Variables	Hypersensitivity	Pancreatitis	GI	Leucopenia	Hepatotoxicity	Infection
patients	25 (7.1)	22 (6.2)	19 (5.4)	13 (3.7)	12 (3.4)	4 (1.1)
Gender
Males	16 (64.0)	9 (40.9)	7 (36.8)	4 (30.8)	4 (33.3)	2 (50.0)
Females	9 (36.0)	13 (59.1)	12 (63.2)	9 (69.2)	8 (66.7)	2 (50.0)
Age at thiopurine (yr)	37.6 (32.3, 47.9)	43.9 (32.2, 48.8)	26.5 (22.8, 47.1)	29.6 (23.6, 47.7)	49 (41.8, 57.9)	24.3 (19.3, 27.1)
Time from prescription to withdrawal of thiopurine (d)	31 (29.0, 65.0)	29 (14.5, 30.0)	17 (7.0, 26.0)	347.5 (159.0, 866.0)	51 (30.0, 70,0)	1907 (603.0, 2718.0)
AZA dose (mg/kg)	2.2 (1.6, 2.4)	2.3 (2.0, 2.4)	2 (1.7, 2.2)	1.6 (0.8, 2.3)	1.3 (0.8, 2.0)	2.1 (2.0, 3.1)

Main reasons leading to discontinuation of thiopurine therapy in 351 patients due to an adverse event. No multiple reasons were recorded. Data are given as median and IQR unless otherwise stated. Other (n = 15, 13.6%) causes for discontinuation were alopecia (n = 3), photosensitivity (n = 1), basal cell carcinoma (n = 2), mood disturbance (n = 1), syncopal episodes (n = 1), fatigue (n = 1), headache (n = 1), eye problems (n = 1) and unknown (n = 4). AZA: Azathioprine; IQR: Interquartile range; GI: Gastrointestinal intolerance.